
Aon plc
AON Financials · No analyses yet
Mentioned in recent filings: Ukraine Russia Tariffs Going-concern doubt
What changed
No articles about this company yet. Follow it to hear when the first one appears.
Sector peers
How this company compares with 39 covered companies in Financials (median revenue change +10.9% YoY), from archived SEC XBRL filings.
| Company | Latest revenue | Revenue YoY | Operating margin |
|---|---|---|---|
| Aon plc AON | — | — | — |
| Berkshire Hathaway Inc BRK-B | $74.3B | +16.6% | — |
| Jpmorgan Chase & Co. JPM | $50.2B | +8.1% | — |
| Visa Inc. V | $45.9B | +14.8% | 61.2% |
| Bank of America Corp BAC | $30B | +3.2% | — |
| Progressive Corp PGR | $23.2B | +3.0% | — |
| Wells Fargo & Company WFC | $21.9B | +2.0% | — |
Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.
Large funds (13F)
| Fund | Shares | Value | Change in shares | Quarter |
|---|---|---|---|---|
| BlackRock | 15,716,429 | $5,212,982,529 | -2.7% | Q2 2026 |
| State Street | 9,416,039 | $3,123,430,849 | +2.1% | Q2 2026 |
| Norges Bank (Norway's sovereign fund) | 2,796,760 | $927,657,324 | — | Q2 2026 |
| Fidelity (FMR) | 551,367 | $182,882,898 | +5.4% | Q2 2026 |
| Millennium Management | 312,198 | $103,552,955 | +1,462.9% | Q2 2026 |
| Wellington Management | 106,370 | $35,281,866 | +16.4% | Q2 2026 |
| Citadel Advisors | 105,569 | $35,016,182 | +31.5% | Q2 2026 |
| D. E. Shaw & Co. | 34,765 | $11,531,203 | -72.9% | Q2 2026 |
| Bridgewater Associates | 15,663 | $5,195,260 | -22.5% | Q2 2026 |
| Renaissance Technologies | 11,601 | $3,744,571 | — | Q1 2026 |
| Two Sigma Investments | 6,297 | $2,088,652 | -67.8% | Q2 2026 |
| T. Rowe Price | 3,136,640 | $1,040,393 | +144.9% | Q2 2026 |
| Baupost Group (Seth Klarman) | 687,000 | $227,871 | -10.7% | Q2 2026 |
From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.
